Breaking News

Octapharma Opens Recombinant Research Facility

Invests $32 million for research and clinical production

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Octapharma AG has opened its $32 million research facility dedicated to recombinant protein drug development in Heidelberg, Germany. Octapharma Biopharmaceuticals GmbH, a subsidiary of Octapharma AG, provides human therapeutic proteins and is among the first to use recombinant technology from human cells. The new location is close to medical and clinical establishments including the German Cancer Research Center (the DKFZ) and Heidelberg University Hospital.   Dr. Ulrich Thibaut, board member R&...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters